Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas

Aggressive pituitary adenomas (APAs) are, by definition, resistant to optimal multimodality therapy. The challenge lies in their early recognition and timely management. Temozolomide is increasingly being used in patients with APAs, but evidence supporting a favorable response with early initiation...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Frontiers in endocrinology (Lausanne) 2021-12, Vol.12, p.774686-774686
Hauptverfasser:	Das, Liza, Gupta, Nidhi, Dutta, Pinaki, Walia, Rama, Vaiphei, Kim, Rai, Ashutosh, Radotra, Bishan Dass, Gupta, Kirti, Sreedharanunni, Sreejesh, Ahuja, Chirag Kamal, Bhansali, Anil, Tripathi, Manjul, Sood, Ridhi, Dhandapani, Sivashanmugam
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenoma - diagnosis Adenoma - drug therapy Adenoma - epidemiology Adenoma - pathology Adult aggressive pituitary adenomas Cohort Studies controlled disease Early Medical Intervention early therapy Endocrinology Female Humans India - epidemiology Male MGMT Middle Aged Neoadjuvant Therapy Neoplasm Invasiveness Pituitary Neoplasms - diagnosis Pituitary Neoplasms - drug therapy Pituitary Neoplasms - epidemiology Pituitary Neoplasms - pathology Prognosis Retrospective Studies temozolomide Temozolomide - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!